Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT07615959

Medicsen Smartpatch: Safety & Performance (SOUNDD)

Sponsor: Medicsensors S.L

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to understand the efficacy of Medicsen's Smartpatch to deliver drugs through the skin in healthy volunteers. The main questions it aims to answer are: * Is the administration with Medicsen Smartpatch safe for the patient? * Can Medicsen's Smartpatch be used to effectively administer drugs to patients? Researchers will compare administration with Medicsen's Smartpatch with the subcutaneous administration of the drug to see if the efficacy and safety are comparable Participants will be asked to fill a tolerability survey after receiving each of the two interventions: Subcutaneous administration and Medicse's Smartpatch. Blood samples will be taken at different timepoints to asses for efficacy of each treatment.

Official title: Clinical Investigation to Evaluate the Safety, Tolerability and Performance of the Medicsen Smartpatch, a Non-Invasive Ultrasound-Based Drug Delivery Medical Device (SOUNDD Study)

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2026-01-20

Completion Date

2026-11

Last Updated

2026-05-29

Healthy Volunteers

Yes

Conditions

Healthy

Interventions

DEVICE

Medicsen Smartpatch

This intervention consists of administering the drug using the Medicsen Smartpatch, a non-invasive, needle-free drug delivery device that utilizes sonophoresis technology to enhance absorption through the skin.

DEVICE

Subcutaneous (SC) single dose

This intervention consists of administering the drug via standard subcutaneous injection using a pre-filled pen injector

Inclusion Criteria: * Subjects must provide signed informed consent prior to participation in any study related procedures * Healthy Caucasian volunteers, any sex, aged between 18 to 55 years * Body Mass Index (BMI) between 18.5 and 30.0 kg/m2 * Ability and agreement to comply with the study requirements * Medical history and physical examination within normal limits. * No clinically relevant abnormalities in hematology, biochemistry, virology, or urine tests. * Participants who engage in sexual activity which could result in pregnancy for themselves or their partner(s) must agree to use highly effective methods of contraception during the clinical investigation. Exclusion Criteria: * Case history of hypersensitivity to medicinal products or any other allergic process that could interfere with study according to the investigator's judgement. * Current relevant disease, including respiratory disease, cardiovascular, endocrine, neurological, haematological, renal, neoplasic, hepatopathy, dermatology, gastrointestinal distress, hypertension, or infectious acute processes that could interfere with study according to the investigator's judgement. * Previous chronic processes or with rebound characteristics that could interfere with study according to the investigator's judgement. * Administration of topic or systemic medication including medicinal plants within 14 days before the intervention. * Presence of skin disorders or lesions at the intended application site (e.g., eczema, psoriasis, infections, open wounds), which may interfere with drug absorption or increase risk of adverse effects. * Implanted electronic medical devices, such as pacemakers or neurostimulators, due to potential interference with ultrasonic energy. * Pregnant or breastfeeding women, due to lack of safety data for either the drug or the ultrasound application in this population. * Severe cognitive or motor impairment, where safe operation of the patch cannot be ensured, unless under continuous caregiver supervision.

Locations (1)

Hospital Universitario Ramon y Cajal

Madrid, Madrid, Spain